Redeye comments on Cereno Scientific’s in-licensing agreement with CS585. The project is still in preclinical development. Therefore, we refrain from including CS585 in our valuation. Redeye maintains its view, and we reiterate our base case of SEK5.1 per share.

Länk till analysen